Roche’s STARGLO study demonstrates Columvi significantly extends survival

Swiss pharma giant Roche (ROG: SIX) presented strong new overall survival data at the European Hematology Association (EHA) 2024 Congress over the weekend on its Columvi (glofitamab).

Roche announced statistically-significant and clinically-meaningful results from its Phase III STARGLO study of Columvi in combination with gemcitabine and oxaliplatin (GemOx) versus Roche’s older therapy MabThera/Rituxan (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy.

In that indication, the drug competes with AbbVie (NYSE: ABBV) and Genmab’s (ONX: GEN) rival CD20xCD3 bispecific Epkinly (epcoritamab), so moving it into the first relapse setting could hand Roche an advantage. Analysts at Jeffries have previously forecast that epcoritamab could rack up the $2.75 billion peak sales, in a competitive space.